Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors - Quiz - MDSpire

Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors

  • By

  • Ting-Kai Liao

  • Wei-Hsun Lu

  • Ping-Jui Su

  • Chih-Jung Wang

  • Ying Jui Chao

  • Yan-Shen Shan

  • May 28, 2026

  • 0 min

Share

Original Source(s)

Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors

  • by Ting-Kai Liao, Wei-Hsun Lu, Ping-Jui Su, Chih-Jung Wang, Ying Jui Chao, Yan-Shen Shan

  • May 28, 2026

Related Content

The impact of the large B-cell lymphoma tumor microenvironment on efficacy of CD19-directed CAR-T immunotherapy

CD169-positive macrophages in lymph nodes and the tumor microenvironment: harnessing their biology for clinical diagnosis and anticancer therapeutic strategies

Case Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma